ABILITY Network Inc.

MINNEAPOLIS, MN · CIK 0001282356 · Biotech

Immune-modulating biotherapeutics for cancer and autoimmune diseases

ability.bio →
Grants
—
No SBIR or STTR on record
Sector median: 1
Raised
$20M
1 Form D · May 2011
185 months since last filing
Contracts
—
No federal contracts on record
Patents
—
No published records under this name
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Private capital raisedForm D · SEC$19,999,998
Form D · SEC

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
1843HCO ANTIBODY, INC.——
1844MARIPOSA HOLDINGS GROUP, INC.—$280K
1845Javelin Oncology, Inc.—$1.5M
1846ABILITY Network Inc.—$20M
1847Biena, LLC—$11M
1848EMMYON, INC.——
1849VITRISTOR LLC——

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Founders & Team

From Form D filings · 15 related persons
  • James BradleyDirector
  • Mark BriggsDirector · Executive Officer
  • Jeff CrisanDirector
  • John FeikemaExecutive Officer
  • Roger HaleDirector
  • Jack HauserExecutive Officer
  • Andy HurdDirector
  • Bud MeadowsExecutive Officer
  • Tony MillerDirector
  • Mark PulidoDirector
  • Buck RogersExecutive Officer
  • Randy SchmidtDirector
  • Steve SmerzExecutive Officer
  • Paul TutenExecutive Officer
  • Chelle WoolleyExecutive Officer

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.